Trial Profile
Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% Compared to Nepafenac Ophthalmic Suspension 0.1% and Vehicle for Prevention and Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2014
Price :
$35
*
At a glance
- Drugs Nepafenac (Primary)
- Indications Ocular inflammation; Postoperative pain
- Focus Therapeutic Use
- Sponsors Alcon
- 12 Dec 2014 New trial record